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Hypoxia and pH influence gene expression in tumours, and it is becoming increasingly clear that the pattern of genes expressed by a
tumour determines its growth and survival characteristics. Hypoxia-inducible factor-1 (HIF-1) is a key mediator of the cellular
response to hypoxia and high HIF-1 expression has been identified as a poor prognostic factor in tumours. Recently, we identified the
tumour-associated carbonic anhydrases (CA), CA9 and CA12 as hypoxia-inducible in tumour cell lines. Furthermore, we identified CA
IX to be a poor prognostic factor in breast cancer. The aim of this study was to assess the prognostic significance of CA XII. CA XII
expression was studied by immunohistochemistry in a series of 103 cases of invasive breast cancer and any association with
recognised prognostic factors or relation with the outcome was examined. CA XII expression was present in 77 out of 103 (75%)
cases and was associated with lower grade (P¼0.001), positive estrogen receptor status (Po0.001), and negative epidermal growth
factor receptor status (Po0.001). Furthermore, although CA XII expression was associated with an absence of necrosis (Po0.001),
expression of CA XII in some high-grade tumours was induced in regions directly adjacent to morphological necrosis. Additionally,
using univariate analysis, CA XII positive tumours were associated with a lower relapse rate (P¼0.04) and a better overall survival
(P¼0.01). In conclusion, CA XII expression is influenced both by factors related to differentiation and hypoxia in breast cancer in vivo
and CA XII expression is associated with a better prognosis in an unselected series of invasive breast carcinoma patients.
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Methods for the detection of breast cancer have improved
markedly over the past decade and patients are subsequently
presenting with ever earlier stages of disease (Ernster and Barclay,
1997). Although established markers of tumour behaviour,
including tumour size and nodal status are applicable for this
group of patients, tissue-based markers that can predict the risk of
progression and recurrence would improve the ability to identify
those who would benefit from the treatment (Bennington et al,
1992; Ernster et al, 1996; Tabar et al, 2000). Indeed, several such
markers, such as tumour grade and estrogen receptor (ER) status
are well established. These factors mostly relate to cellular
differentiation, while alternative indicators of the metabolic status
of tumour cells, such as oxygenation, are relatively sparse (Brizel
et al, 1997; Vaupel and Hoeckel, 1999). Necrosis is one such
indicator of poor oxygenation and has been shown to be a
prognostic indicator (Leek et al, 1999). However, necrosis is
nonspecific, and may not always be associated with severe hypoxia
(Mueller-Klieser et al, 1983; Parliament et al, 1997; Ramanujan
et al, 2000). To identify endogenous hypoxic markers that might
have utility as prognostic indicators, we and others have begun to
examine the expression patterns of known hypoxia-inducible
genes in tumour specimens. Potential markers include the oxygen-
regulated subunits of the transcriptional complex hypoxia-
inducible factor-1 (HIF-1), a key mediator of the hypoxic response,
HIF-1a and HIF-2a, or HIF-1 target genes (Shweiki et al, 1992;
Maxwell et al, 1997; Zhong et al, 1999).
Recently, we extended the range of HIF-1 target genes by
identifying the two tumour-associated transmembrane carbonic
anhydrases (CA) CA9 (Opavsky et al, 1996; Ivanov et al, 1998) and
CA12 (Ivanov et al, 1998; Tureci et al, 1998) as upregulated by
hypoxia in a range of epithelial cancer cell lines (Wykoff et al,
2000). Carbonic anhydrases catalyse the reversible hydration of
carbon dioxide to carbonic acid, providing a potential link
between metabolism and pH regulation. We were therefore
interested in examining the expression of these CA in tumour-
igenesis and progression in breast cancer. Our initial studies
focused on CA IX as this gene demonstrated a more dramatic
hypoxic induction in the tumour cell lines examined (Wykoff et al,
2000). CA IX expression was closely correlated with the presence of
necrosis in both in situ and invasive cancer (Chia et al, 2001;
Wykoff et al, 2001), and was found to be an independent predictor
of relapse-free and overall survival (Chia et al, 2001). In the present
study, we have investigated CA XII expression in breast cancer in
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ythe anticipation that its expression might also serve as an indicator
of tissue hypoxia and tumour progression. Specifically, we wished
to assess the pattern of expression in invasive breast carcinoma
and the relation to outcome.
MATERIALS AND METHODS
Patients and tissues
A series of 103 surgically resected invasive breast carcinomas was
assessed for CA XII expression in sections from paraffin tissue
blocks. The clinicopathologic characteristics of this cohort are
representative of that of a general population of breast cancer
patients and are summarised in Table 1. The distribution of
tumour types was 87% invasive ductal, 11% invasive lobular, and
2% special type (mucinous and tubular). All cases had previously
been treated at the John Radcliffe Hospital and the Churchill
Hospital, Oxford, and all cases underwent either modified radical
mastectomy or lumpectomy with breast irradiation for primary
treatment. Axillary lymph node positive cases also received
adjuvant radiotherapy to the axillary region. Adjuvant systemic
treatment consisted of endocrine therapy (for all postmenopausal
women regardless of hormonal receptor status and comprising
Tamoxifen at 20mg daily for 5 years) or chemotherapy (compris-
ing six cycles of intravenous cyclophosphamide, methotrexate and
5-fluorouracil delivered every 3 weeks). All patients were assessed
by follow-up every 3 months for the first 18 months and then every
6 months thereafter. Treatment for confirmed recurrent disease
was by endocrine therapy for soft tissue or skeletal metastasis or
by chemotherapy for visceral disease and failed endocrine therapy.
Assessment of tumour grade, necrosis, and hormone
receptor status
Tumour grade and necrosis was scored on haematoxylin- and
eosin-stained sections immediately adjacent to those sections
subjected to immunohistochemistry. Tumour grade was assessed
using the Nottingham system (Elston and Ellis, 1991). The entire
section was also assessed for the percentage of necrosis present
within the invasive tumour component. Both parameters were
scored by a single pathologist (PHW) independently from the IHC
analysis and blinded to the cohort’s clinical data and outcome.
Necrosis was assessed semiquantitatively by estimating the area of
the tumour section involved by light microscopy. Necrosis within
in situ carcinoma components was not scored. For statistical
analysis the percentage of necrosis was either assessed as a
continuous variable or divided into negative or positive (where the
presence of any necrosis was considered positive). Estrogen
receptor (ER) analysis was performed using an enzyme linked
immunosorbent assay technique (Abbott Laboratories, Chicago,
USA). Epidermal growth factor receptor (EGFR) was determined
using ligand binding of [
125I] EGF to tumour membranes (Fox et al,
1994). Tumours with an EGFR level greater than or equal to
20fmolmg
 1of membrane protein and ER greater than or equal to
10fmolmg
–1 of cytosol protein were considered positive.
Immunohistochemistry (IHC)
Immunohistochemical staining for CA XII was performed on 5mm
serial sections on coated slides from paraffin-embedded blocks.
The anti-CA XII antibody (Kivela et al, 2000a; Tureci et al, 1998)
has previously been characterised and we have also further
confirmed its ability to specifically detect CA XII expression in
tissue sections by correlation with Western blot analysis in human
breast tumour specimens (Wykoff et al, 2001). All slides were first
deparaffinised and then placed in 0.5% hydrogen peroxide for
15min to saturate endogenous peroxidases. Incubation with 10%
normal human serum in Tris buffered saline (TBS) for 15min was
then performed to block nonspecific uptake of the antibody. The
anti-CA XII antibody (Kivela et al, 2000a) was used at a dilution of
1:50 in TBS with 5% normal human serum for 30min. Next, a
30min incubation with a peroxidase conjugated to goat anti-
mouse immunoglobulins (Dako EnVision+System, Peroxidase,
Mouse; Dako, Carpinteria, CA, USA) was performed. Slides were
then stained with 3,3-diaminobenzidine chromogen solution for
8min and then counterstained with haematoxylin and mounted
with aquamount. All staining was performed on an automated
immunohistochemical stainer (MiniPrep 75, Tecan; Reading, UK)
at room temperature (RT). Following successive incubations
(except the normal human serum block) the slides were washed
twice with TBS for 5min.
Assessment of CA XII expression
Immunostaining for CA XII was quantified by light microscopy
and semiquantitative scoring by one author (PHW) blinded to the
cohort’s clinical data and outcome. In brief, a score of 0–3 was
assigned for the intensity of staining assessed at low-power
magnification ( 10 objective; 0: no staining; 1: weak staining; 2:
moderate staining; and 3: strong staining). The percentage of
invasive tumour cells that were stained positive was then estimated
at both low and high magnification and the product of the
intensity of staining and the percentage of tumour positive cells
was then calculated to produce an immunostaining score (IHC
score) of 0–300.
Table 1 Clinical and pathological characteristics
Patient characteristics Number
Total patients 103
Age (median, range) (years) 59 (28–83) years
o50 27
>50 76
Surgical treatment
Lumpectomy 5
Lumpectomy+RT 63
Mastectomy 35
Tumor size (median, range) (cm) 2.4cm (0.8–8cm)
o24 3
>2 58
Node status
Positive (number positive nodes) 58 (1–16)
Negative 45
Grade
11 5
24 8
34 0
ER status
Positive 70
Negative 33
EGFR status
Positive 56
Negative 46
Adjuvant therapy
Chemotherapy 27
Hormonal therapy (Tamoxifen) 80
Median duration follow-up (median, range) 6.2 (0.4–10.1)
Relapses 41
Deaths 32
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For statistical analysis CA XII expression was evaluated as a
continuous variable using the IHC-score. CA XII was also assessed
as a categorical variable using the median (IHC score 440) to
distinguish low from high expression. CA XII was evaluated in
relation to a range of established prognostic variables using
Mann–Whitney and Kruskal–Wallis tests where appropriate. The
association with relapse-free and overall survival was assessed by
univariate (log-rank test and Kaplan–Meier method) and multi-
variate (Cox’s regression model) analysis.
RESULTS
CA XII expression in relation to clinicopathological
variables
The specificity of the rabbit anti-human CA XII antisera for
detection of CA XII in breast tissue sections was initially confirmed
by comparison of IHC scores with the detection of 46–48kDa
bands corresponding to CA XII by immunoblotting performed on
the same tumour specimens (Wykoff et al, 2001). CA XII
expression was observed in 77 out of 103 (75%) cases of invasive
carcinoma with a wide distribution of IHC scores (range 0–270,
median 40, mean 65). Immunostaining was restricted to membra-
nous staining of epithelial tumour cells and the pattern of
expression was usually homogeneous. Representative examples
of tumours showing overall low, moderate and high CA XII
expression are illustrated in Figure 1.
CA XII expression was compared with several established
clinical–pathological prognostic variables. When CA XII was
assessed as a continuous variable, there was a strong correlation
between CA XII expression and tumour grade (r¼ 0.39,
Po0.0001 Spearman’s test), ER level (r¼0.53, Po0.0001), EGFR
(r¼ 0.38, Po0.0001) and extent of necrosis (r¼ 0.44,
Po0.0001). When CA XII was assessed as a categorical variable
these relations were also evident, with high CA XII expression
significantly associated with lower tumour grade, positive ER
Figure 1 Expression of CA XII in invasive breast tumours. The panels show representative examples of CA XII expression detected by IHC in three
invasive ductal carcinomas. The cases were associated with overall IHC scores of 10 (A and B), 100 (C and D), and 225 (E and F) respectively. Panels on
the right side (B, D and F) are higher magnifications to show cellular detail within the corresponding tumour shown on the left. Original magnifications; left
 40, right  200.
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Despite the negative association between overall CA XII staining
and necrosis, accentuation of CA XII expression was sometimes
observed in tumour cells immediately adjacent to areas of necrosis
within both in situ and invasive components (Figure 1), as
might be predicted from our previous in vitro studies with
tissue-culture cells (Wykoff et al, 2000). However, this express-
ion pattern was typically present only focally in high-grade
tumours where the overall level of CA XII within the tumour
was low. No other significant relation with other prognostic
variables such as age, nodal status, tumour size, or tumour type
were observed.
Relation of CA XII expression to relapse-free survival
and overall survival
Univariate analysis was conducted to explore the relation of CA
XII to established prognostic factors and to survival. The relation
of several conventional factors with survival in this cohort of cases
was first confirmed. Nodal status, grade, and ER status were all
significantly related to both relapse-free survival (P-
values¼o0.001, 0.04, 0.03, respectively) and overall survival (P-
values¼o0.001, 0.04, 0.02, respectively) in this series. In addition,
tumour size (relapse-free survival, P¼0.04) and patient age
(overall survival, P¼0.05) were also predictive of aspects of
survival. Further analysis, considering CA XII expression as a
categorical value (IHC score 0, CA XII negative; IHC score 40, CA
XII positive), showed a significant association between CA XII
positive tumours and a longer relapse-free survival (P¼0.04) and
a better overall survival (P¼0.01) (Figure 3). In addition,
subgroup analysis showed that the presence of CA XII expression
was also a significant predictor of both longer relapse-free and
better overall survival for tumours without necrosis (P¼0.04, 0.04,
Figure 4).
We were unable to demonstrate an independent influence in
multivariate Cox’s proportional hazard analysis when CA XII,
lymph node status, grade, ER status and necrosis were all
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Figure 2 Association of CA XII with ER, EGFR, necrosis and grade. Each box indicates the range of CA XII IHC score from the 25th percentile to the 75th
percentile, the line indicates the median, and the whiskers above and below the box show the highest and lowest values.
Relapse-free survival by CAXII
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Time (years) 
CAXII=Neg.
CAXII=Pos.
P=0.04
n=52
n=51
Overall survival by CAXII
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
02 4 8 6
024 8 6
Time (years) 
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
CAXII=Neg.
CAXII=Pos.
P=0.01
n=52
n=51
Figure 3 Kaplan – Meier curves demonstrating a relation between CA
XII and relapse-free and overall survival within the entire cohort.
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these factors, only lymph node status emerged as an independent
predictor of survival in this cohort of patients.
DISCUSSION
In this study, we have shown that CA XII is frequently expressed in
invasive breast carcinoma, where expression is strongly associated
with several good prognostic parameters, including low tumour
grade, ER-positive status, EGFR-negative status, and absence of
necrosis.
These findings extend our previous observations that expression
of CA XII is closely related to tumour differentiation in pre-
invasive in situ ductal breast carcinomas (DCIS), where CA XII was
observed to be highest in well differentiated and reduced in
poorly differentiated lesions (Wykoff et al, 2001). Further-
more, although CA XII expression was generally low or absent in
high-grade tumours with necrosis, we observed that focal
induction of CA XII can be present in tumour cells adjacent to
necrosis. This is consistent with our previous observations in in
situ breast carcinoma (Wykoff et al, 2001) and similar observa-
tions made by others in invasive breast carcinoma (Ivanov et al,
2001), and with our in vitro findings that CA XII is regulated to
some degree by hypoxia in breast tumour cells (Wykoff et al,
2000).
CA XII is widely expressed in specialised cells within normal
tissues (Ivanov et al, 2001) and in several different tumour types
(Tureci et al, 1998; Kivela et al, 2000a,b; Ivanov et al, 2001). In one
previous study of 29 breast cancers, CAXII was found to be focally
expressed in normal breast and expressed in 62% of invasive
carcinomas, primarily in low-grade tumours (Ivanov et al, 2001).
In the normal colon and associated cancers, CA XII expression was
frequently found in superficial regions of normal colonic mucosal
epithelium, and was found to persist at comparable levels within
preinvasive and invasive lesions (Kivela et al, 2000a). Although no
significant association was seen with tumour grade, it should be
noted that relatively small subgroups were available for analysis of
invasive carcinoma and that the cranial–caudal location of each
lesion may also have influenced expression. Despite this, a trend
was observed towards reduced expression in high- vs low-grade
adenoma, complementing our findings in preinvasive breast
cancer (Wykoff et al, 2001). In contrast to this pattern of
decreasing expression with increasing grade, Kivela et al (2000a)
observed increased expression in nonsurface, deep cryptal
epithelium with progression from normal through in situ to
invasive disease, between low- and high-grade adenomas, and in
higher stage invasive tumours. It is interesting to speculate that
both these regional differences and the increased expression of CA
XII in deeper regions within adenomas and colon carcinomas
might relate to differences in vascularity, oxygenation and relative
hypoxia.
Although other members of the CA gene family have been
examined in several tumour types (Nogradi, 1998), and it is known
that the increased expression of CA IX is associated with aspects of
early tumourigenesis in cervix, colon and lung tumours (Liao and
Stanbridge, 1996; Saarnio et al, 1998; Vermylen et al, 1999), a
prognostic role for CA has not previously been identified in breast
cancer. Our recent studies have shown that increased CA IX
expression is associated with poor relapse free and overall survival
in invasive breast cancer (Chia et al, 2001). CA IX expression is
also closely related to necrosis. Necrosis may be attributable to
several factors (Mueller-Klieser et al, 1983; Parliament et al, 1997;
Ramanujan et al, 2000), but an important factor is likely to be
hypoxia and the relation between CA IX and necrosis is consistent
with the recently described relation between HIF-1a and prognosis
in tumours (Zhong et al, 1999). However, the results of the current
study indicate that while hypoxia may influence CA XII expression
in focal areas discernable within high-grade breast tumours, the
regulation of CA XII by differentiation-related factors appears to
be dominant in vivo. Consequently, CA XII is associated with
several phenotypic characteristics consistent with well differen-
tiated tumours and good overall survival, at least in univariate
analysis. The relatively small size of the series limited the capacity
to study CA XII and prognosis within subsets of tumours with
otherwise good prognosis. However, CA XII appears also to be a
discriminator of good outcome within tumours that are negative
for necrosis. Our results suggest that further examination of the
role of CA XII as a prognostic marker may be warranted within
certain subgroups of patients. The possibility that CA XII
expression may also be relevant to chemotherapy response in
such cases should also be considered, since an acidic extracellular
pH can reduce uptake and efficacy of doxorubicin (Raghunand
et al, 1999).
In conclusion, we have shown that CA XII is frequently
expressed in invasive breast carcinoma and that focal
enhancement of expression can be observed adjacent to areas of
necrosis, supporting the notion that CA XII is a hypoxia regulated
gene in vivo. However, the dominant factors in CA XII regulat-
ion are clearly related to tumour differentiation and higher
levels of CA XII expression are associated well with differentiated
tumours and with a better relapse-free and overall survival. In
view of the known differences in extracellular pH (Gerweck, 1998)
and the contrasting patterns of expression observed for CA IX
and XII in normal and neoplastic breast tissues (Wykoff et al,
2001), it will be important to explore the prognostic significance
of CA XII further, in concert with other carbonic anhydrases and
in relation to specific chemotherapies that may be influenced
by extracellular pH (Raghunand et al, 1999), in larger prospective
studies.
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Figure 4 Kaplan – Meier curves demonstrating an association of CA XII
with outcome within subgroups of tumours with and without necrosis.
Carbonic anhydrase XII in invasive breast carcinoma
PH Watson et al
1069
British Journal of Cancer (2003) 88(7), 1065–1070 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yACKNOWLEDGEMENTS
The authors would like to thank Mrs Lesley Richards for secretarial
assistance with this manuscript. This work was supported by the
Imperial Cancer Research Fund and the Wellcome Trust. PHW is
supported by a Scientist Award from the Medical Research Council
of Canada, an Academic Award from the US Army Medical
Research and Materiel Command (USAMRMC), and a Research
Travel Fellowship from Burroughs Welcome. SKC is supported by
the Shane Fellowship and the Canadian Breast Cancer Foundation
– British Columbia/Yukon Chapter.
REFERENCES
Bennington JL, Lagios MD, Margolin FR (1992) Impact of mammographic
screening on the size and the relative frequency of invasion in breast
cancers seen in a community hospital from 1975–1988. Pathology (Phila)
1: 11–21
Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumour
hypoxia adversely affects the prognosis of carcinoma of the head and
neck. Int J Radiat Oncol Biol Phys 38: 285–289
Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC,
Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia
regulated marker – carbonic anhydrase IX in invasive breast carcinoma. J
Clin Oncol 19: 3660–3668
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer.
I. The value of histological grade in breast cancer: experience from a
large study with long-term follow-up. Histopathology 19: 403–410
Ernster VL, Barclay J (1997) Increases in ductal carcinoma in situ (DCIS) of
the breast in relation to mammography: a dilemma. J Natl Cancer Inst
Monogr 22: 151–156
Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996)
Incidence of and treatment for ductal carcinoma in situ of the breast [see
comments]. JAMA 275: 913–918
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL (1994) The
epidermal growth factor receptor as a prognostic marker: results of 370
patients and review of 3009 patients. Breast Cancer Res Treat 29: 41–49
Gerweck LE (1998) Tumour pH: implications for treatment and novel drug
design. Semin Radiat Oncol 8: 176–182
Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N,
Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J,
Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of
hypoxia-inducible cell-surface transmembrane carbonic anhydrases in
human cancer. Am J Pathol 158: 905–919
Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ,
Lerman MI (1998) Down-regulation of transmembrane carbonic
anhydrases in renal cell carcinoma cell lines by wild-type von Hippel–
Lindau transgenes. Proc Natl Acad Sci USA 95: 12 596–12 601
Kivela A, Parkkila S, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK, Waheed
A, Sly WS, Grubb JH, Shah G, Tureci O, Rajaniemi H (2000a) Expression
of a novel transmembrane carbonic anhydrase isozyme XII in normal
human gut and colorectal tumours. Am J Pathol 156: 577–584
Kivela AJ, Parkkila S, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK,
Pastorekova S, Pastorek J, Waheed A, Sly WS, Rajaniemi H (2000b)
Expression of transmembrane carbonic anhydrase isoenzymes IX and
XII in normal human pancreas and pancreatic tumours. Histochem Cell
Biol 114: 197–204
Leek RD, Landers RJ, Harris AL, Lewis CE (1999) Necrosis correlates with
high vascular density and focal macrophage infiltration in invasive
carcinoma of the breast. Br J Cancer 79: 991–995
Liao SY, Stanbridge EJ (1996) Expression of the MN antigen in cervical
papanicolaou smears is an early diagnostic biomarker of cervical
dysplasia. Cancer Epidemiol Biomarkers Prev 5: 549–557
Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ,
Hankinson O, Pugh CW, Ratcliffe PJ (1997) Hypoxia-inducible factor-1
modulates gene expression in solid tumours and influences both
angiogenesis and tumour growth. Proc Natl Acad Sci USA 94: 8104–8109
Mueller-Klieser W, Freyer JP, Sutherland RM (1983) Evidence for a major
role of glucose in controlling development of necrosis in EMT6/Ro
multicell tumour spheroids. Adv Exp Med Biol 159: 487–495
Nogradi A (1998) The role of carbonic anhydrases in tumours [comment].
Am J Pathol 153: 1–4
Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada
J, Kettmann R, Pastorek J (1996) Human MN/CA9 gene, a novel member
of the carbonic anhydrase family: structure and exon to protein domain
relationships. Genomics 33: 480–487
Parliament MB, Franko AJ, Allalunis-Turner MJ, Mielke BW, Santos CL,
Wolokoff BG, Mercer JR (1997) Anomalous patterns of nitroimidazole
binding adjacent to necrosis in human glioma xenografts: possible role of
decreased oxygen consumption. Br J Cancer 75: 311–318
Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-
Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ (1999) Enhancement of
chemotherapy by manipulation of tumour pH. Br J Cancer 80: 1005–
1011
Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK (2000) Local
imbalance of proangiogenic and antiangiogenic factors: a potential
mechanism of focal necrosis and dormancy in tumours. Cancer Res 60:
1442–1448
Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J,
Kairaluoma MI, Karttunen TJ (1998) Immunohistochemical study of
colorectal tumours for expression of a novel transmembrane carbonic
anhydrase, MN/CA IX, with potential value as a marker of cell
proliferation [see comments]. Am J Pathol 153: 279–285
Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth
factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
Nature 359: 843–845
Tabar L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA
(2000) A novel method for prediction of long-term outcome of women
with T1a, T1b, and 10–14mm invasive breast cancers: a prospective
study. Lancet 355: 429–433
Tureci O, Sahin U, Vollmar E, Siemer S, Gottert E, Seitz G, Parkkila AK,
Shah GN, Grubb JH, Pfreundschuh M, Sly WS (1998) Human carbonic
anhydrase XII: cDNA cloning, expression, and chromosomal localization
of a carbonic anhydrase gene that is overexpressed in some renal cell
cancers. Proc Natl Acad Sci USA 95: 7608–7613
Vaupel P, Hoeckel M (1999) Predictive power of the tumour oxygenation
status. Adv Exp Med Biol 471: 533–539
Vermylen P, Roufosse C, Burny A, Verhest A, Bosschaerts T, Pastorekova S,
Ninane V, Sculier JP (1999) Carbonic anhydrase IX antigen differentiates
between preneoplastic malignant lesions in non-small cell lung
carcinoma. Eur Respir J 14: 806–811
Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Wilson GD,
Turley H, Maxwell PH, Ratcliffe P, Harris AL (2000) Hypoxia inducible
expression of tumour associated carbonic anhydrases. Cancer Res
60:7075–7083
Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek
J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-
inducible and tumour-associated carbonic anhydrases in ductal carci-
noma in situ of the breast. Am J Pathol 158: 1011–1019
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D,
Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression
of hypoxia-inducible factor 1alpha in common human cancers and their
metastases. Cancer Res 59: 5830–5835
Carbonic anhydrase XII in invasive breast carcinoma
PH Watson et al
1070
British Journal of Cancer (2003) 88(7), 1065–1070 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y